US Stock MarketDetailed Quotes
TRDA Entrada Therapeutics
- 12.450
- +0.090+0.73%
Close Apr 26 16:00 ET
- 12.450
- 0.0000.00%
Post 16:20 ET
418.33MMarket Cap-62250P/E (TTM)
12.730High12.100Low25.82KVolume12.100Open12.360Pre Close322.98KTurnover0.17%Turnover RatioLossP/E (Static)33.60MShares18.44052wk High1.73P/B187.61MFloat Cap10.62052wk Low--Dividend TTM15.07MShs Float36.850Historical High--Div YieldTTM5.10%Amplitude5.120Historical Low12.509Avg Price1Lot Size
Entrada Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 249.07%139.8M | 85.30%-4.01M | 10.88%-24.49M | -94.85%-35.09M | 1,068.98%203.4M | -84.39%-93.79M | -32.92%-27.3M | -95.25%-27.48M | -127.67%-18.01M | -151.81%-20.99M |
| Net income from continuing operations | 92.93%-6.69M | 61.25%-9.54M | 241.07%35.46M | -11.86%-25.93M | 69.20%-6.67M | -84.95%-94.62M | -33.51%-24.63M | -74.20%-25.14M | -134.11%-23.18M | -158.60%-21.67M |
| Depreciation and amortization | 49.92%2.84M | 39.92%736K | 61.63%834K | 57.67%730K | 38.72%541K | 69.65%1.9M | 44.51%526K | 70.86%516K | 83.73%463K | 95.98%390K |
| Change In working capital | 1,326.85%136.32M | 149.39%2.95M | -1,025.92%-62.33M | -652.24%-11.32M | 12,676.79%207.01M | -224.79%-11.11M | -55.82%-5.98M | -716.52%-5.54M | 45.08%2.05M | -415.99%-1.65M |
| -Change in receivables | ---5.88M | ---853K | ---1.28M | --2.55M | ---6.3M | --0 | --0 | --0 | --0 | --0 |
| -Change in prepaid assets | 161.49%8.62M | 725.17%12.52M | -55.36%-14.78M | 881.03%6.55M | 359.82%4.34M | -108.26%-14.02M | 68.14%-2M | -1,332.53%-9.51M | -398.22%-838K | -2,430.30%-1.67M |
| -Change in payables and accrued expense | -28.63%5.03M | 3,240.64%8.39M | -248.21%-5.92M | -191.39%-2.07M | 767.48%4.64M | 117.09%7.05M | -68.55%251K | 86.34%4M | 109.43%2.27M | 168.77%535K |
| -Change in other current assets | -87.14%426K | 146.70%1.03M | -6.23%1.82M | 11.97%2.87M | -619.71%-5.3M | 1,100.91%3.31M | -239.07%-2.21M | 200.31%1.94M | 28,588.89%2.56M | 4,334.78%1.02M |
| -Change in other current liabilities | -59.20%-11.86M | 141.76%841K | -101.63%-3.96M | -249.79%-6.79M | -27.37%-1.95M | ---7.45M | ---2.01M | ---1.96M | ---1.94M | ---1.53M |
| -Change in other working capital | --139.98M | ---18.97M | ---38.21M | ---14.43M | --211.58M | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 249.07%139.8M | 85.30%-4.01M | 10.88%-24.49M | -94.85%-35.09M | 1,068.98%203.4M | -84.39%-93.79M | -32.92%-27.3M | -95.25%-27.48M | -127.67%-18.01M | -151.81%-20.99M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 6.90%-138.4M | 1.34%19.04M | 63.12%-3.74M | -567.52%-113.26M | 77.72%-40.44M | -3,145.63%-148.65M | 1,521.48%18.79M | -1,157.32%-10.13M | 1,668.98%24.23M | -19,892.62%-181.53M |
| Net PPE purchase and sale | -94.46%-5.61M | -37.85%-976K | -78.77%-1.45M | -96.39%-1.52M | -180.81%-1.67M | 36.97%-2.89M | 46.44%-708K | -0.50%-810K | 49.81%-775K | 34.58%-594K |
| Net investment purchase and sale | 8.91%-132.78M | 2.66%20.02M | 75.45%-2.29M | -546.94%-111.74M | 78.57%-38.78M | ---145.76M | --19.5M | ---9.32M | --25M | ---180.94M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 6.90%-138.4M | 1.34%19.04M | 63.12%-3.74M | -567.52%-113.26M | 77.72%-40.44M | -3,145.63%-148.65M | 1,521.48%18.79M | -1,157.32%-10.13M | 1,668.98%24.23M | -19,892.62%-181.53M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 4,291.86%21.04M | 92.74%690K | 513.33%368K | 3,927.27%443K | 38,972.00%19.54M | -99.84%479K | -99.81%358K | -43.40%60K | -94.88%11K | -99.96%50K |
| Net common stock issuance | --19.41M | --0 | --0 | --0 | --19.41M | --0 | --0 | --0 | --0 | --0 |
| Proceeds from stock option exercised by employees | 240.29%1.63M | 92.74%690K | 513.33%368K | 3,927.27%443K | 158.00%129K | -48.99%479K | 459.38%358K | -43.40%60K | -98.26%11K | -63.50%50K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 4,291.86%21.04M | 92.74%690K | 513.33%368K | 3,927.27%443K | 38,972.00%19.54M | -99.84%479K | -99.81%358K | -43.40%60K | -94.88%11K | -99.96%50K |
| Net cash flow | ||||||||||
| Beginning cash position | -83.13%49.11M | -2.50%55.83M | -11.73%83.69M | 161.43%231.6M | -83.13%49.11M | 645.46%291.06M | -53.13%57.26M | -30.76%94.82M | -39.40%88.59M | 645.46%291.06M |
| Current changes in cash | 109.28%22.45M | 292.79%15.72M | 25.81%-27.86M | -2,475.22%-147.91M | 190.13%182.49M | -196.01%-241.96M | -104.83%-8.15M | -154.19%-37.56M | 167.40%6.23M | -288.98%-202.47M |
| End cash Position | 45.71%71.55M | 45.71%71.55M | -2.50%55.83M | -11.73%83.69M | 161.43%231.6M | -83.13%49.11M | -83.13%49.11M | -53.13%57.26M | -30.76%94.82M | -39.40%88.59M |
| Free cash flow | 238.81%134.19M | 82.19%-4.99M | 8.31%-25.94M | -94.92%-36.61M | 1,034.59%201.73M | -74.37%-96.67M | -28.13%-28.01M | -90.12%-28.29M | -98.69%-18.78M | -133.50%-21.59M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg